The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Advanced human immunodef iciency virus (HIV) infection, despite sustained viral suppression by highly active antiretroviral therapy (HAART), is a risk factor for poor immunologic recovery. However, some patients with advanced infection do show immunologic recovery. In this study, predictive factors of immunologic recovery were analyzed in advanced HIV patients showing sustained viral suppression. Methods: A case-control study was conducted in HIV-infected adult patients with HIV-1 RNA < 50 copies/mL maintained for 4 years or longer and who were receiving HAART. Advanced HIV infection was defined as a baseline CD4 T cell count < 200/mm3. Immunologic responders were defined as patients showing immunologic recovery (CD4 T cell counts ≥ 500/mm3 at 4 years with HAART). To analyze the CD4 T cell kinetics, the CD4 slope (monthly changes in the CD4 T cell count) was estimated for each patient using a linear regression between the CD4 T cell count and the time since HAART initiation. Results: Of 102 eligible patients, 73 had advanced HIV, and 33 (45.2%) showed immunologic recovery. The median CD4 slopes (cells/mm3 per month) during 0 to 6 and 0 to 12 months of HAART in the 73 advanced patients were significantly higher in responders than in non-responders (0 to 6 months, 38.6 vs. 22.8; 0 to 12 months, 24.5 vs. 13.5). Multivariate analyses showed opportunistic infections at the start of HAART (adjusted odds ratio [OR], 0.28) and a CD4 slope ≥ 20 during 0 to 12 months of HAART (adjusted OR, 10.10) were independently associated with immunologic recovery. Conclusions: The CD4 slope can be an early predictor of long-term immunologic recovery in advanced HIV patients.
Abstract
Background/Aims: Advanced human immunodef iciency virus (HIV) infection, despite sustained viral suppression by highly active antiretroviral therapy (HAART), is a risk factor for poor immunologic recovery. However, some patients with advanced infection do show immunologic recovery. In this study, predictive factors of immunologic recovery were analyzed in advanced HIV patients showing sustained viral suppression. Methods: A case-control study was conducted in HIV-infected adult patients with HIV-1 RNA < 50 copies/mL maintained for 4 years or longer and who were receiving HAART. Advanced HIV infection was defined as a baseline CD4 T cell count < 200/mm3. Immunologic responders were defined as patients showing immunologic recovery (CD4 T cell counts ≥ 500/mm3 at 4 years with HAART). To analyze the CD4 T cell kinetics, the CD4 slope (monthly changes in the CD4 T cell count) was estimated for each patient using a linear regression between the CD4 T cell count and the time since HAART initiation. Results: Of 102 eligible patients, 73 had advanced HIV, and 33 (45.2%) showed immunologic recovery. The median CD4 slopes (cells/mm3 per month) during 0 to 6 and 0 to 12 months of HAART in the 73 advanced patients were significantly higher in responders than in non-responders (0 to 6 months, 38.6 vs. 22.8; 0 to 12 months, 24.5 vs. 13.5). Multivariate analyses showed opportunistic infections at the start of HAART (adjusted odds ratio [OR], 0.28) and a CD4 slope ≥ 20 during 0 to 12 months of HAART (adjusted OR, 10.10) were independently associated with immunologic recovery. Conclusions: The CD4 slope can be an early predictor of long-term immunologic recovery in advanced HIV patients.
참고문헌 (27)
- The Gap Report, "Joint United Nations Programme on HIV", AIDS(UNAIDS), AIDS, pp.2014, ~
- Corbeau P, "Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection", Blood, 117, pp.5582~ (2011)
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents" (2015)[URL]
- Broder S., "The development of antiretroviral therapy and its impact on the HIV-1", AIDS pandemic, 2010, pp.85, 1~18
- Chun TW, "Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy", Proc Natl Acad Sci U S A, 94, pp.13193~13197 (1997)
- Chun TW, "Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection", Proc Natl Acad Sci U S A, 95, pp.8869~8873 (1998)
- Guihot A, "Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy", AIDS, 24, pp.614~617 (2010)
- Autran B, "Restoration of the immune system with anti-retroviral therapy", Immunol Lett, 66, pp.207~211 (1999)
- Guihot A, "Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus", Trends Immunol, 32, pp.131~137 (2011)
- Kaufmann GR, "CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study", Arch Intern Med, 163, pp.2187~2195 (2003)
- Tsukamoto H, "Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects", Proc Natl Acad Sci U S A, 106, pp.18333~18338 (2009)
- Viard JP, "Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study", J Infect Dis, 183, pp.1290~1294 (2001)
- Egger M, "Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:a collaborative analysis of prospective studies", Lancet, 360, pp.119~129 (2002)
- Nicastri E, "Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART", J Med Virol, 76, pp.153~160 (2005)
- Lawn SD, "CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa", BMC Infect Dis, 6, pp.59~ (2006)
- Rajasuriar R, "Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database", PLoS One, 6, pp.e20713~ (2011)
- Havlir DV, "Prevalence and predictive value of intermittent viremia with combination hiv therapy", JAMA, 286, pp.171~179 (2001)
- Kelley CF, "Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment", Clin Infect Dis, 48, pp.787~794 (2009)
- "1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults", MMWR Recomm Rep, 41(RR-17), pp.1~19 (1992)
- Kaufmann GR, "Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells", microL in HIV type 1-infected individuals receiving potent antiretroviral therapy, 2005, pp.41, 361~372
- "Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents" (2015)[URL]
- Morris L, "Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients", J Infect Dis, 187, pp.1967~1971 (2003)
- Autran B, "Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease", Science, 277, pp.112~116 (1997)
- Carcelain G, "Reconstitution of CD4+T lymphocytes in HIV-infected individuals following antiretroviral therapy", Curr Opin Immunol, 13, pp.483~488 (2001)
- Pido-Lopez J, "Both age and gender affect thymic output: more recent thymic migrants in females than males as they age", Clin Exp Immunol, 125, pp.409~413 (2001)
- Hoffmann CJ, "CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa", J Acquir Immune Defic Syndr, 63, pp.34~41 (2013)
- Kaufmann GR, "The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy", AIDS, 16, pp.359~367 (2002)